ClinicalTrialsFinder

Tumors Clinical Trials in Houston, Texas

137 recruitingHouston, Texas

Showing 1–20 of 137 trials

Recruiting
Phase 1Phase 2

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled65 locationsNCT05768139
Recruiting
Phase 1Phase 2

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.27 enrolled6 locationsNCT07192432
Recruiting
Phase 1

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Triple Negative Breast Cancer(TNBC)HR+ Breast CancerHR+/HER2- Breast Cancer+1 more
NiKang Therapeutics, Inc.361 enrolled14 locationsNCT07029399
Recruiting
Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast CancerOvarian CancerColorectal Carcinoma+4 more
AstraZeneca45 enrolled18 locationsNCT05877599
Recruiting
Phase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled15 locationsNCT06993844
Recruiting
Phase 1Phase 2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1

IDOV-Immune for Advanced Solid Tumors

Breast CancerColorectal, CancerEsophageal Cancer+13 more
ViroMissile, Inc.78 enrolled6 locationsNCT06910657
Recruiting
Phase 1

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Triple-Negative Breast CancerOvarian CancerAdvanced Solid Tumors+2 more
Accent Therapeutics90 enrolled5 locationsNCT06799065
Recruiting
Phase 1

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

Triple Negative Breast Cancer(TNBC)Advanced Solid Tumors Cancer
ProteinQure Inc.80 enrolled4 locationsNCT07190469
Recruiting
Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerOvarian Cancer+6 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 2

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
Phase 1Phase 2

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Advanced Solid Tumors
LigaChem Biosciences, Inc.300 enrolled8 locationsNCT05941507
Recruiting
Phase 1

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Triple-Negative Breast CancerBreast NeoplasmsLung Cancer+7 more
Circle Pharma220 enrolled10 locationsNCT06577987
Recruiting
Phase 1Phase 2

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Advanced Solid Tumors
Eikon Therapeutics130 enrolled10 locationsNCT06907043
Recruiting
Phase 1

PRE-I-SPY Phase I/Ib Oncology Platform Program

Triple-Negative Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+18 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226